Australia's largest stock trading and investment forum Australia's #1 stock forum

ASW

Click for more information

0.00%

17.0¢ advanced share registry limited

I guess the best one can do is assume that it follows the...

First 3 Last

Share
Profile

Follow
MarsC

4,233 Posts.

455

16/06/17

18:35

Post #: 25325160
Share

Originally posted by madamswer ↑

Not a very enlightening upgrade, I have to say.
(In fact, a downright confusing one.)

To the extent that the JH2017 result has been adversely impacted by an investment in costs that relate to increasing capacity for growth is not the least concerning to me (in fact, as a shareholder, I welcome and applaud it).

But that turnover for the full-year is expected to be "comparable with previous periods" is disconcertingly vague, because I don't know what is meant by "previous periods" (plural).

For here are Revenue figures for some of the most recent "previous periods"

DH2015: $2.98m
JH2016: $3.08m
DH2016: $3.36m
JH2017: $3.0m (like DH2015 and JH2016)? or $3.4m (like DH2016)? (Which one?)

Or, if one was to interpret the announcement as referring to full-year figures, and it is saying that FY2017 Revenue is to be comparable to FY2016's $6.1m, then it implies that JH2017 Revenue of around $2.70m, which would be around 12% down on pcp.

Each one of those varying interpretations generate some starkly different implications for the way the business is performing.

It is really a poorly-worded announcement.

Expand

I guess the best one can do is assume that it follows the pattern of the recent past.

So I take that to mean revenue in H2 FY17 to be 10% to 20% less than that of H1 FY17. Now if costs have gone up relative to pcp's, then clearly NPAT will be something else again.

ASW Price at posting: 77.0¢ Sentiment: Hold Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

There are more pages in this discussion • 12 more messages in this thread...

First 3 Last

Add ASW (ASX) to my watchlist